CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study

Warfarin anticoagulation effect is characterized by marked variability, some of which has been attributed to CYP2C9 polymorphisms. This study prospectively examines whether a priori knowledge of CYP2C9 genotype may improve warfarin therapy. Patients were randomly assigned to receive warfarin by a va...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2008-03, Vol.83 (3), p.460-470
Main Authors: Caraco, Y, Blotnick, S, Muszkat, M
Format: Article
Language:English
Subjects:
Adult
Aged
Anticoagulants - adverse effects
Aryl Hydrocarbon Hydroxylases - genetics
Biological and medical sciences
Cohort Studies
Cytochrome P-450 CYP2C9
Drug Prescriptions
Female
Genotype
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Prospective Studies
Warfarin - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Warfarin anticoagulation effect is characterized by marked variability, some of which has been attributed to CYP2C9 polymorphisms. This study prospectively examines whether a priori knowledge of CYP2C9 genotype may improve warfarin therapy. Patients were randomly assigned to receive warfarin by a validated algorithm (“control”, 96 patients) or CYP2C9 genotype‐adjusted algorithms (“study”, 95 patients). The first therapeutic international normalized ratio and stable anticoagulation were reached 2.73 and 18.1 days earlier in the study group, respectively (P
ISSN:0009-9236
1532-6535
DOI:10.1038/sj.clpt.6100316